Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 221 for:    Aldosterone

Plasma Aldosterone Levels and Atrial Fibrillation Reduction (ALDO-AF Study) (ALDO-AF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02804321
Recruitment Status : Unknown
Verified June 2016 by University Hospital, Caen.
Recruitment status was:  Recruiting
First Posted : June 17, 2016
Last Update Posted : June 17, 2016
Sponsor:
Information provided by (Responsible Party):
University Hospital, Caen

Brief Summary:

Atrial fibrillation (AF) is the most common cardiac arrhythmias with a constantly growing prevalence. Two main techniques are used today to restore sinus rhythm: electrical cardioversion and radiofrequency ablation.

Radiofrequency ablation has become a recognized and effective treatment of AF. Despite a relatively high success rate (about 80%), a substantial number of patients require a second procedure to obtain sinus rhythm. Many publications have led to the study of predictors of failure of this ablation factors (BMI, uncontrolled hypertension, size of the OG...) but to date no parameter is reliable and usable in daily practice.

It is the same for electrical cardioversion. Despite a relatively high immediate success rate of approximately 80%, a significant number of patient relapse arrhythmia in short and long term. Many publications have led to the study of predictive factors of failure (seniority and type of AF, uncontrolled hypertension, size of the OG, mitral valve disease...) but so far the results are disappointing.

In AF patients with heart disease underlying, it has been well demonstrated that the renin-angiotensin system (RAAS) was strongly activated. In addition, it is now well established that elevated plasma aldosterone as in primary hyperaldosteronism is associated with a significantly increased risk of occurrence of cardiovascular events. The high plasma concentrations were also highlighted in the acute phase of myocardial infarction, or heart failure and are associated with an increase in major cardiovascular event rate, especially arrhythmias. In some experimental models of heart failure, it has been demonstrated a suppression of the occurrence of spontaneous FA by an anti-aldosterone treatment. The arrhythmogenic effect of aldosterone has also been shown in animal models. All these results indicate a potential role of aldosterone in the genesis of an arrhythmogenic substrate and the FA.

The hypothesis of this study is that aldosterone plasma levels in pre-reduced patients is predictive of recurrence risk of atrial fibrillation or other supraventricular tachycardias (flutter or atrial tachycardia) after FA reduction, either in using a radiofrequency ablation or via electrical cardioversion.


Condition or disease
Atrial Fibrillation Aldosterone

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 170 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 6 Months
Official Title: Plasma Aldosterone Levels and Atrial Fibrillation Reduction (ALDO-AF Study)
Study Start Date : September 2013
Estimated Primary Completion Date : September 2017
Estimated Study Completion Date : November 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Aldosterone




Primary Outcome Measures :
  1. recurrence of supraventricular tachycardia (atrial fibrillation, atrial flutter and atrial tachycardia) after atrial fibrillation reduction by radiofrequency ablation or electrical cardioversion. [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Find a correlation between recurrence of supraventricular tachycardia and plasmatic aldosterone level before cardioversion [ Time Frame: 6 months ]
  2. Find a correlation between recurrence of supraventricular tachycardia and plasmatic ngal level before cardioversion [ Time Frame: 6 months ]
  3. Find a correlation between recurrence of supraventricular tachycardia and plasmatic galectin-3 level before cardioversion [ Time Frame: 6 months ]
  4. Find a correlation between recurrence of supraventricular tachycardia and occurrence of cardiovascular events [ Time Frame: 6 months ]
  5. Find a correlation between recurrence of supraventricular tachycardia and occurrence of renal failure [ Time Frame: 6 months ]

Biospecimen Retention:   Samples Without DNA
aldosterone galectine 3 ngal


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The study population corresponds to all patients referred for atrial fibrillation cardioversion by radiofrequency ablation or electrical cardioversion, clinically stable, at Caen University Hospital, Pitié-Salpêtrière and Ambroise Paré clinic.

These patients have a strict, rigorous and systematic follow after these cardioversion at 1, 3 and 6 months with routine ECG.

Criteria

Inclusion Criteria:

  • Patients referred for atrial fibrillation cardioversion by radiofrequency ablation or electrical cardioversion
  • scheduled hospitalisation or hospitalisation unrelated to cardiovascular events
  • Age at least 18 years
  • Clinically Stable (see criteria for non-inclusion)

Exclusion Criteria:

  • Patient unstable defined as any cardiovascular event that occurred in the previous 30 days

These events are:

  • hospitalisation for cardiovascular causes
  • appearance or worsening of symptoms consistent with cardiac failure
  • appearance or worsening symptoms of coronary

    • Patient refusing participation in the study
    • Patient unable to provide follow-up visits

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02804321


Contacts
Layout table for location contacts
Contact: Joachim Alexandre, MD alexandre-j@chu-caen.fr

Locations
Layout table for location information
France
Alexandre Joachim Recruiting
Caen, Basse Normandie, France, 14000
Contact: Joachim Alexandre, MD       alexandre-j@chu-caen.fr   
Sponsors and Collaborators
University Hospital, Caen

Additional Information:

Layout table for additonal information
Responsible Party: University Hospital, Caen
ClinicalTrials.gov Identifier: NCT02804321     History of Changes
Other Study ID Numbers: A13-D37-VOL.18
First Posted: June 17, 2016    Key Record Dates
Last Update Posted: June 17, 2016
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Keywords provided by University Hospital, Caen:
catheter ablation
galectin 3
ngal
aldosterone
atrial fibrillation
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes